Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.

INTRODUCTION Hemophilia A is routinely treated by administration of exogenous coagulation factor VIII (FVIII). As safety and efficacy of FVIII products have improved over the years, development of FVIII-neutralizing antibodies (FVIII inhibitors) has emerged as the most serious complication. The new human cell line-derived recombinant human FVIII (human-cl… CONTINUE READING